• DNDi - Best Science for the Most Neglected 20 Years
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • COVID-19
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
DNDi - Best Science for the Most Neglected 20 Years
  • DNDi - Best Science for the Most Neglected 20 Years
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • COVID-19
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > News

R&D status November 2015: DNDi Leishmaniasis programme

27 Nov 2015
Share on twitter
Share on facebook
Share on linkedin
Share on email
Share on print

The parasite that causes leishmaniasis is transmitted by the bite of a sandfly. Leishmaniasis is a complex group of diseases with over a million new cases occurring every year and 350 million people living at risk worldwide in 98 countries. The most common forms of the disease are visceral leishmaniasis (VL), which is fatal without treatment, and cutaneous leishmaniasis (CL).

India, Bangladesh, Ethiopia, South Sudan, Sudan, and Brazil account for 90% of all reported cases of VL. Existing treatments are either difficult to administer, toxic, or costly. Drug resistance is also an increasing problem. PKDL is a skin lesions disease which mostly affects individuals after treatment for VL. Up to 50% of all VL patients in Sudan and 5-10% patients in India and Bangladesh develop PKDL, which may play a major role in disease transmission between epidemics. The WHO Roadmap (2012) and the Indian revised National Kala-Azar Elimination Roadmap have set the objective to eliminate VL from the Indian subcontinent.

DNDi’s current leishmaniasis portfolio includes:

Research

Research

Four projects in the research phase:

  • Nitroimidazoles: This project aims to identify nitroimidazole backups to compounds that are currently in translation phase. DNDi-0690, a nitroimidazole for the treatment of VL and possibly CL, was selected for preclinical development on 1 September 2015 and may have improved properties compared to earlier compounds of the same class
  • Oxaleish: The most advanced oxaboroles for treating VL and possibly CL (‘oxaleish’) are nearing completion of the lead optimization and profiling phases. The aim is to select the most promising compound from this class during the next twelve months.
  • Aminopyrazoles: The aminopyrazole class of compounds has shown promising early profiles for the treatment of both VL and CL. Lead optimization is ongoing to identify a pre-clinical candidate from this class.
  • Leish H2L: This project continues to evaluate hits identified from screening and to begin the process of optimizing these new chemical series. If promising activity can be demonstrated in in vivo models of leishmaniasis, the series will be advanced into full lead optimization. This process of ‘hit to lead’ optimization is ongoing with multiple series from several pharmaceutical companies.

Translation
Translation

Five projects in the translation phase:

  • Fexinidazole/miltefosine combination: Fexinidazole and miltefosine are foreseen as the first combination of two oral drugs for VL, under development in East Africa. Before proceeding to a proof-of-concept (PoC) study in patients, a drug-drug interaction (DDI) study to assess pharmacokinetics and safety of the combination will be conducted in up to 60 healthy volunteers.  A pharmacokinetic and safety study of miltefosine in 30 children completed recruitment in August 2015. A previous study carried out in Africa showed that dose adjustment was required for children, as results indicated under-exposure in this group compared to adults. Adjusted doses of fexinidazole will be also be assessed (increasing efficacy within safety limits). If the DDI study shows the combination is safe, a PoC study will be initiated in patients to assess its efficacy and safety in primary VL cases.
  • Fexi-sulfone: Fexinidazole is converted extensively in vivo to an active metabolite called fexinidazole sulfone. This compound may offer some advantages for the treatment of VL compared to fexinidazole, such as reaching effective blood concentrations in patients more quickly and with less variability, or improving side-effects. DNDi has evaluated fexinidazole sulfone in an in vivo efficacy model and an assessment of the overall strategy for its development will be considered along with other candidate molecules before deciding to proceed to clinical trials.
  • CpG-D35 for CL: Having been taken up in DNDi’s portfolio in 2014, this project aims at producing an immunomodulator to stimulate the innate immune system to fight the parasitic infection as an adjunct to drug therapy. The project has made progress and non-GMP batches were produced to start toxicological and immunological studies.
  • New CL combinations: The safety and efficacy profiles of the current CL treatments (antimonials, miltefosine, and thermotherapy) when administrated alone are very well established. Using a combination of therapeutic approaches may both improve efficacy rates, reduce treatment duration, and improve the rate of adverse events. DNDi will soon begin to test a combination of one single application of thermotherapy at 50 degrees Celsius for 30 minutes combined with a short course (3 weeks) of oral miltefosine.
  • Anfoleish for CL: A Phase II study with Anfoleish, a topical cream containing amphotericin B started in 2014 at one site in Colombia to assess the safety, pharmacokinetics (PK), and efficacy of the cream in patients with CL caused by L. braziliensis and L. panamensis (since 2015). Following the safety data of the first 30 subjects enrolled in the study, recommendation was made to continue the study. Forty additional patients have been enrolled since then.

Two projects were interrupted:

  • In 2013, VL-2098 was identified among the nitroimidazoles as a very potent molecule and was expected to enter into Phase I after positive results of the toxicology/safety analysis. However, after following comprehensive review of the VL-2098 testicular toxicity data in in vivo models, the decision was taken to stop the study.
  • The Phase II proof-of-concept study with fexinidazole for the treatment of adult primary VL patients in Sudan, which aimed to evaluate drug efficacy and establish safety and pharmacokinetic/pharmacodynamic (PK/PD) profiles, was interrupted. The doses selected for the study were identical to those of the Phase II/III Human African Trypanosomiasis trial. Enrolment began in November 2013 and ended in May 2014, with a total of 164 patients screened and 14 enrolled in the study. Treatment was very well tolerated. Majority of patients had an initial good clinical response with a negative test of cure by microscopy at the end of treatment. However, this response was not sustained, and relapses were observed in the follow-up period. New regimens including fexinidazole are currently being explored to improve efficacy, within safety limits (see fexinidazole/miltefosine combination).

Development
Development

 Four projects in the development phase:

  • A Phase III study of treatments for HIV/VL co-infection (132 patients), testing a combination treatment (AmBisome and miltefosine, and monotherapy with AmBisome at a higher dose than current practice) had started in 2014 at two sites in Ethiopia. Neither treatment regimen was able to achieve the targeted efficacy rate thus the decision was taken to interrupt the study.
  • A Phase II study of two treatments, AmBisome monotherapy and in combination with miltefosine, for Post-Kala-Azar Dermal Leishmaniasis (PKDL) to assess the safety and efficacy for treatments of patients in India and Bangladesh, is currently under development.
  • A Phase III study (sponsored by the Brazilian Ministry of Health) with new VL treatments based on combination therapies[1]for the treatment of VL patients in Brazil started in 2011 at five sites and recruited 380 patients. The national guidelines for VL were revised in 2013 based on the interim safety data from the trial. Glucantime remains the first-line treatment, while AmBisome replaced Amphotericin B deoxycholate as second-line treatment. Final results of this trial are under analysis.
  • MSF, in collaboration with DNDi and the Rajendra Memorial Research Institute of Medical Sciences (RMRI), is planning to initiate a Phase III study testing AmBisome monotherapy and the combination of AmBisome and miltefosine to treat HIV/VL in India.
 

Implementation
Implementation

 Implementation and access to treatments:

  • DNDi also continues to support the implementation of SSG&PM, a combination VL treatment for Africa delivered in 2010 by DNDi and the Leishmaniasis East Africa Platform (LEAP). Whereas this combination was recommended as first-line therapy for VL patients in East Africa by the WHO Expert Committee on the Control of Leishmaniases in 2010 and by the most affected countries, DNDi continues to support registration efforts, notably of paromomycin (PM), and treatment availability to VL patients in the region. PM is registered in Kenya and Uganda. In Sudan and Ethiopia, the registration dossier is still under submission to the regulatory authorities. SSG is registered in Kenya, Uganda, and Sudan, and a dossier was submitted in Ethiopia. In Ethiopia (SSG and PM) and Sudan (SSG), the drugs can be imported, as they were included in the national essential medicines lists.
  • In Asia, DNDi and partners, working closely with the Indian government, have provided data from an implementation study (1761 enrolled patients) to support policy change expressed in the revised National Kala-Azar Elimination Roadmap, which recommends the use of AmBisome single infusion in areas of high prevalence and paromomycin/miltefosine combination as appropriate in low prevalence districts. Follow-up visits continue to assess long-term efficacy and identify development of PKDL.

Among its activities, DNDi joined in 2015 the Consortium for the Control and Elimination of Visceral Leishmaniasis, known as KalaCORE, a new partnership between DNDi, the London School of Hygiene and Tropical Medicine (LSHTM), Médecins Sans Frontières (MSF), and Mott MacDonald. The consortium has been appointed by the Department for International Development (DFID) to deliver its programme over the next four years in six countries (India, Bangladesh, Nepal, Ethiopia, Sudan, and South Sudan) supporting national efforts and coordinating with national VL control programmes.

For more information on the partners and donors involved in DNDi’s Leishmaniasis programme, please click on each hyperlink that will refer you to each project.


[1] Amphotericin B deoxycholate, AmBisome, and AmBisome combined with Glucantime, as compared to the first-line treatment, Glucantime.

DNDi aims to deliver from its leishmaniasis-specific portfolio:

  • An oral, safe, effective, low-cost and short-course treatment
  • A new treatment for Post-Kala-Azar Dermal Leishmaniasis (PKDL) that is shorter course and better tolerated than current options
  • A new treatment regimen for patients co-infected with HIV and VL
  • A safe, effective, and shorter-course treatment for CL
Cutaneous leishmaniasis Visceral leishmaniasis

Read, watch, share

Loading...
Davide Paparo and Ian Hausler with their thermotherapy device "CLARA"
Stories
16 Mar 2023

Cutaneous leishmaniasis: Swiss students develop innovative thermotherapy device for safer treatment of ‘flesh-eating parasite’

Stories
8 Mar 2023

Highlighting gender-based treatment gaps on International Women’s Day: Mary Alamak’s story

DNDi-GARDP Southern Africa director, Carol Ruffell (left), presents the December 2022 edition of HIV Nursing Matters and the 2022 paediatric ARV dosing chart to Bénédicte Schutz, Monaco’s Director of International Cooperation (centre), and Yordanos Pasquier, Monaco’s Deputy Director of International Cooperation (right).
News
3 Mar 2023

Working together to ensure optimal treatment for children living with HIV in South Africa

Nurse with patient
Press releases
1 Mar 2023

Fiocruz and DNDi sign strategic alliance agreement

Statements
28 Feb 2023

DNDi’s submission to the Technical Assessment component of the first Global Stocktake

Statements
22 Feb 2023

DNDi comments on the zero draft of the WHO CA+ for consideration of the Intergovernmental Negotiating Body at INB4 & 5

Hat Platform Newsletter N°22 screenshot
Publications
22 Feb 2023

HAT Platform Newsletter No. 22

Lab activities
News
20 Feb 2023

First in-person Dengue Alliance meeting brings together experts from dengue-endemic countries to develop treatments for a growing viral threat

VIEW ALL

Help neglected patients

To date, we have delivered twelve new treatments, saving millions of lives.

Our goal is to deliver 25 new treatments in our first 25 years. You can help us get there. 

GIVE NOW
DNDi - Best Science for the Most Neglected 20 Years
Facebook-f
Twitter
Instagram
Linkedin-in
Youtube
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • Neglected tropical diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License   
We use cookies to track our audience and improve our content. By clicking 'Accept All', you are agreeing to our use of cookies. Click on 'Customize' to accept only some cookies.
Customize
ACCEPT ALL
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-advertisement1 yearSet by the GDPR Cookie Consent plugin, this cookie is used to record the user consent for the cookies in the "Advertisement" category .
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
CookieLawInfoConsent1 yearRecords the default button state of the corresponding category & the status of CCPA. It works only in coordination with the primary cookie.
PHPSESSIDsessionThis cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
CookieDurationDescription
elementorneverThis cookie is used by the website's WordPress theme. It allows the website owner to implement or change the website's content in real-time.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
CookieDurationDescription
_ga2 yearsThe _ga cookie, installed by Google Analytics, calculates visitor, session and campaign data and also keeps track of site usage for the site's analytics report. The cookie stores information anonymously and assigns a randomly generated number to recognize unique visitors.
_ga_16Q5RH3XRG2 yearsThis cookie is installed by Google Analytics.
_gat_UA-10302561-11 minuteA variation of the _gat cookie set by Google Analytics and Google Tag Manager to allow website owners to track visitor behaviour and measure site performance. The pattern element in the name contains the unique identity number of the account or website it relates to.
_gid1 dayInstalled by Google Analytics, _gid cookie stores information on how visitors use a website, while also creating an analytics report of the website's performance. Some of the data that are collected include the number of visitors, their source, and the pages they visit anonymously.
_hjAbsoluteSessionInProgress30 minutesHotjar sets this cookie to detect the first pageview session of a user. This is a True/False flag set by the cookie.
_hjFirstSeen30 minutesHotjar sets this cookie to identify a new user’s first session. It stores a true/false value, indicating whether it was the first time Hotjar saw this user.
_hjIncludedInPageviewSample2 minutesHotjar sets this cookie to know whether a user is included in the data sampling defined by the site's pageview limit.
_hjIncludedInSessionSample2 minutesHotjar sets this cookie to know whether a user is included in the data sampling defined by the site's daily session limit.
_hjSession_112884430 minutesHotjar sets this cookie.
_hjSessionUser_11288441 yearHotjar sets this cookie.
CONSENT2 yearsYouTube sets this cookie via embedded youtube-videos and registers anonymous statistical data.
Targeting
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
SAVE & ACCEPT
Powered by CookieYes Logo